Scattered news nudged a few biotechs on a fairly static day for health stocks Friday.
Endo Pharmaceuticals(ENDP) said late Thursday that the Food and Drug Administration requested an extension on the review date of its new-drug application for the short-term indication of its menstrual migraine drug Frova. The agency already requested an extension earlier this year, pushing the date back from May 19 to Aug. 19. Endo and partner Vernalis said that the FDA hasn't asked them for more information or trial data, and until they receive further information from the agency, they intend to continue their original commercial plan for the drug. Investors didn't seem concerned Friday as shares traded up 47 cents, or 1.5%, to $31.29. The company is a component of the Nasdaq biotechnology index, which was up 11.72, or 1.5%, at 796.18. Anesiva(ANSV) climbed Friday after announcing it received FDA approval of Zingo, a needle-pain reducer for children. Shares climbed 42 cents, or 8.2%, to $5.61. Ventana Medical Systems(VMSI) said Friday that the U.S. District Court in the Eastern District of Massachusetts ruled that Ventana isn't liable for antitrust claims that were brought on by CytoLogix. The company is liable for about $10.8 million in patent infringement damages related to a 2003 decision that found Ventana's Benchmark instrument infringed on two CytoLogix patents. Shares rose $1.15, or 1.5%, to $79.65.TheStreet Premium Services For Personal Service: 877-471-2967
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 12,890.46 | 1,351.95 | 2,927.23 | 20.47 |
Oil *
118.75
|
|
UP
6.51 |
UP
1.99 |
UP
11.37 |
UP
0.72 |
10 Yr
2.05%
SPDR Gold
168.02
|
|
+0.05%
|
+0.15%
|
+0.39%
|
+3.65%
|
Data delayed 20 minutes |

Connect with TheStreet